Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Study of Volociximab (M200) in Combination with Gemcitabine in Metastatic Pancreatic Cancer
2004-004243-21Phase 2Completed
- Sponsor
- PDL BioPharma
- Start
- Apr 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of volociximab in pancreatic adenocarcinoma (PDAC), sponsored by PDL BioPharma. Primary endpoint: Confirmed tumor response rate. Started Apr 2005; status: completed.
02
Drugs
volociximab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2004-004243-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004243-21.